<div id="readability-page-1"><p>H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on Disc Medicine today and set a price target of $118.00.</p><h3>Meet Your ETF AI Analyst</h3><ul><li> Discover how TipRanks' <i>ETF</i> AI Analyst  can help you make smarter investment decisions </li><li>   Explore ETFs TipRanks' users love  and see what insights the <b><i>ETF</i> AI Analyst</b> reveals about the ones you follow.</li></ul> <p>Tsao covers the Healthcare sector, focusing on stocks such as Protagonist Therapeutics, Hansa Biopharma AB, and Alkermes. According to TipRanks, Tsao has an average return of <span>22.0%</span> and a 53.85% success rate on recommended stocks. </p> <p>The word on The Street in general, suggests a Strong Buy analyst consensus rating for Disc Medicine with a $114.91 average price target.</p></div>

IRON

<p>H.C. Wainwright analyst Douglas Tsao maintains a Buy rating on Disc Medicine with a price target of $118.00. Tsao, who covers the Healthcare sector, has an average return of 22.0% and a 53.85% success rate. The analyst consensus suggests a Strong Buy rating for Disc Medicine with an average price target of $114.91.</p>

H.C. Wainwright Remains a Buy on Disc Medicine (IRON)